In a deal worth $7.8 billion, Gilead Sciences has entered a definitive agreement to acquire Arcellx, a biotech company developing a cell therapy for multiple myeloma.
Gilead announced the acquisition agreement a few months after Arcellx published positive data from its lead drug candidate’s phase 2 trial. In December, the biotech said its experimental cell therapy, anitocabtagene autoleucel (anito-cel), achieved a 95% minimal residual disease negativity rate.
Kite, a Gilead company, has an existing collaboration to codevelop and co-commercialize anito-cel, according to a Feb. 23 news release from Gilead.
Arcellx’s and Gilead’s respective boards of directors have approved the acquisition. The transaction is expected to close during the second quarter of 2025.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
